Floatz logo

Tinengotinib

Thyroid Cancer

TransThera Sciences (Nanjing), Inc.Small moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

41 Active assets in the Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kineta Inc.
Phase 2BB
ALECTINIB
Hoffmann-La Roche
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Denosumab
Amgen
Phase 2B
[18F]F-RESCA-T4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

Tinengotinib is also rated in:

cholangiocarcinomaDormant
B
Indicative ·
59 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →